HIV incidence in the United States, 1978-1999

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 2, 2002, Pages 188-201

  Quan, Vu Minh ^a,b   Steketee, Richard W ^c   Valleroy, Linda ^a   Weinstock, Hillard ^a   Karon, John ^a   Janssen, Robert ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Epidemiology; Gay men; Heterosexuals; HIV; Incidence; Injection drug users; Prevalence; Seroconversion; Surveillance; United States

Indexed keywords

ARTICLE; CLINICAL TRIAL; CORRELATION COEFFICIENT; HEALTH SURVEY; HETEROSEXUALITY; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INTRAVENOUS DRUG ABUSE; META ANALYSIS; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE; STATISTICAL ANALYSIS; UNITED STATES; VIRUS TRANSMISSION;

EID: 0036797102     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200210010-00010     Document Type: Article

References (95)

1. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000:355:1158-9.
2. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1999;48(RR-13):1-28.
3. Centers for Disease Control and Prevention. Current trends update: Public Health Service Workshop on Human T-Lymphotropic Virus Type III Antibody Testing - United States. MMWR Morb Mortal Wkly Rep 1985;34:477-8.
4. Centers for Disease Control and Prevention. Provisional Public Health Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985;34:1-5.
5. Centers for Disease Control and Prevention. National HIV serosurveillance summary: results through 1990. Vol. 2. Atlanta: US Department of Health and Human Services, 1991.
6. Centers for Disease Control and Prevention. National HIV serosurveillance summary: results through 1992. Vol. 3. Atlanta: US Department of Health and Human Services, 1993:1-51.
7. Centers for Disease Control and Prevention. National HIV serosurveillance summary: update - 1993. Vol. 3. Atlanta: US Department of Health and Human Services, 1995.
8. Centers for Disease Control and Prevention. National HIV prevalence surveys, 1997 summary. Atlanta: Centers for Disease Control and Prevention, 1998:1-25.
9. Otten MW, Jr, Zaidi AA, Peterman TA, et al. High rate of HIV seroconversion among patients attending urban sexually transmitted disease clinics. AIDS 1994:8:549-53.
10. McFarland W, Kellogg TA, Dilley J, et al. Estimation of human immunodeficiency virus (HIV) seroincidence among repeat anonymous testers in San Francisco. Am J Epidemiol 1997;146:662-4.
11. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-8.
12. Kellerman S, Wortley P, Fleming P. The changing epidemic of HIV. Current Infectious Disease Reports 2000;2:457-65.
13. Chambers JM, Cleveland WS, Kleiner B, et al. Graphical methods for data analysis. Monterey, CA: Wadsworth International Group, 1983.
14. Cleveland WS. The elements of graphing data. Monterey, CA: Wadsworth Advanced Books and Software, 1985.
15. Hessol NA, Lifson AR, O'Malley PM, et al. Prevalence, incidence and progression of human immunodeficiency virus infection in homosexual and bisexual men in hepatitis B vaccine trials, 1978-1988. Am J Epidemiol 130:1167-75.
16. Stevens CE, Taylor PR, Zang EA, et al. Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City. JAMA 1986;255:2167-72.
17. Schwarcz S, Kellogg T, McFarland W, et al. Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: application of the serologic testing algorithm for recent HIV seroconversion. Am J Epidemiol 2001;153:925-34.
18. Monterroso ER, Wu J, Byers B, et al. Effectiveness of HIV prevention programs in the Collaborative Injection Drug Users Studies (CIDUS) [abstract 23171]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
19. Garfein RS, Williams IT, Monterroso ER, et al. Hepatitis C and B virus (HCV, HBV) and human immunodeficiency virus (HIV) infections among young, street-recruited injection drug users (IDUs): the Collaborative Injection Drug Users Study (CIDUS II) [abstract 115]. Presented at the 10th International Symposium on Viral Hepatitis and Liver Disease, Atlanta, April 2000.
20. Gellert GA, Maxwell RM, Higgins KV, et al. HIV infection in the Women's Jail, Orange County, California, 1985 through 1991. Am J Public Health 1993;83:1454-6.
21. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86:642-54.
22. Ragni MV, Winkelstein A, Kingsley L, et al. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B. Blood 1987;70:786-90.
23. Andes WA, Daul CB, DesShazo RD, et al. Seroconversion to human immunodeficiency virus (HIV) in hemophiliacs - relation to lymphadenopathy. Transfusion 1988;28:98-102.
24. Kroner BL, Rosenberg PS, Aledort LM, et al. HIV-1 infection incidence among persons with hemophilia in the United States and Western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:279-86.
25. Winkelstein W, Samuel M, Padian NS, et al. The San Francisco Men's Health Study III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-1986. Am J Public Health 1987:77:685-9.
26. Kingsley LA, Zhou SY, Bacellar H, et al. Temporal trends in human immunodeficiency virus type 1 seroconversion 1984-1989. A report from the Multicenter AIDS Cohort Study (MACS). Am J Epidemiol 1991;134:331-9.
27. Des Jarlais DC, Marmor M, Friedman P, et al. HIV incidence among injecting drug users in New York City, 1992 to 1997: evidence for a declining epidemic. Am J Public Health 2000;90:352-9.
28. Nelson K, Strathdee SA, Celentano D. Temporal trends, demographic and behavioral risk factors for HIV incidence among injection drug users in Baltimore, 1988-1997. Am J Epidemiol 1999;149(Suppl):S10.
29. Davis SF, Rosen DH, Steinberg S, et al. Trends in HIV prevalence among childbearing women in the United States, 1989-1994. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:158-64.
30. McQuillan GM, Khare M, Karon JM, et al. Update on the seroepidemiology of human immunodeficiency virus in the United States household population: NHANES III, 1988-1994. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:355-60.
31. Weinstock H, Sweeney S, Satten GA, et al, for the STD Clinic HIV Seroincidence Study Group. HIV seroincidence and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States. 1991 to 1996. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:506-12.
32. Dean L, Meyer I. HIV prevalence and sexual behavior in a cohort of New York City gay men (aged 18-24). J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:208-11.
33. Koblin BA, Avrett S, Taylor PE, et al. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:165-71.
34. Torian LV, Murrill CS, Makki HA, et al. High HIV seroincidence in nonwhite bisexual men making repeat visits to a New York City sexually transmitted disease clinic, 1994-1995: results of a blinded longitudinal survey [abstract 177]. In Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997.
35. Menzies I, Makki H, Murrill C, et al. Differences in HIV incidence by risk exposure and gender in patients accepting confidential HIV testing at two New York City (NYC) Department of Health (DOH) sexually transmitted disease (STD) clinics, 1994-1998 [abstract 476]. In Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January/February 1999.
36. Haley CE, Freeman A, Anderson P, et al. Incidence of HIV-1 infections among homosexual men in Dallas, Texas, 1987-1988 [abstract TAP21]. In Program and abstracts of the Fifth International Conference on AIDS, Montreal, June 1989.
37. Buchbinder SP, Douglas JM, Jr, McKiman DJ, et al. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis 1996;174:954-61.
38. Winkelstein W, Jr, Wiley JA, Padian NS, et al. The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health 1988;78:1472-4.
39. Osmond DH, Page K, Wiley J, et al. HIV infection in homosexual and bisexual men 18 to 29 years of age; the San Francisco Young Men's Health Study. Am J Public Health 1994;84:1933-7.
40. Osmond D, Charlebois E, Page-Shafer K, et al. Increasing risk behavior has not led to higher HIV incidence rates in the San Francisco Young Men's Health Study: 1993-1998 [abstract 23115]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
41. McFarland W, Busch M, Kellogg TA, et al. Detection of early HIV infection and estimation of incidence using a sensitive/lesssensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr 1999;22:484.
42. Tabet SR, Krone MR, Paradise MA, et al. Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). AIDS 1998;12:2041-8.
43. Swenson PD, Goldbaum G, Ferrell N, et al. Use of less sensitive Abbott 3A11 HIV-1 EIA to measure HIV incidence in King County. In Program and abstracts of the Conference on Laboratory Aspects of Human Retrovirus and Hepatitis C Testing, Charlotte, NC, March 2000.
44. Valleroy L, MacKellar D, Mei J, et al. High HIV incidence among 15- to 22-year-old men who have sex with men in 7 US cities [abstract TuPeC3402]. In Program and abstracts of the XIII Conference on AIDS, Durban, South Africa, July 2000.
45. Seage GR III, Metzger D, Holte S, et al. Feasibility of conducting HIV-1 vaccine trials in the United States: recruitment, retention and HIV-1 seroincidence from the HIV Network for Prevention Trials (HIVNET) Vaccine Preparedness Study (VPS) [abstract 43543]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
46. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:175-6.
47. Murrill C, Prevots R, Miller M, et al. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health 2001;78:152-61.
48. Des Jarlais DC, Friedman SR, Marmor M, et al. Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS 1987;1:105-11.
49. Schoenbaum EE, Hartel DM, Gourevitch MN. Needle exchange use among a cohort of injecting drug users. AIDS 1996;10:1729-34.
50. Siddiqui NS, Brown LS, Meyer TJ, et al. Decline in HIV-1 seroprevalence and low seroconversion rate among injecting drug users at a methadone maintenance program in New York City. J Psychoactive Drugs 1993;25:245-50.
51. Orr MF, Glebatis D, Friedmann P, et al. Incidence of HIV infection in a New York City methadone maintenance treatment program [letter]. JAMA 1996;276:99.
52. Marmor M, Titus S, Wolfe H, et al. Preparations for AIDS vaccine trials; retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res Hum Retroviruses 1994;10(Suppl 2):S207-13.
53. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programs. Lancet 1996;348:987-91.
54. Monterroso ER, Hamburger ME, Vlahov D, et al., for the Collaborative Injection Drug User Study (CIDUS). Prevention of HIV infection in street-recruited injection drug users. J Acquir Immune Defic Syndr 2000;25:63-70.
55. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users inand out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:1049-56.
56. Metzger D, Woody GE, Galai N, et al. Incidence of HIV infection among injection drug users in Philadelphia [abstract 23192]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
57. Meyers K, Metzger DS, McLellan AT, et al. Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:577-85.
58. Chitwood DD, Griffin D, McCoy CB, et al. Incidence and prevalence of HIV-1 in injection drug users in Miami: a four year panel study [abstract PO-C15-2959]. In Program and abstracts of the IX International Conference on AIDS, Berlin, June 1993.
59. Nelson KE, Vlahov D, Galai N, et al. Preparation for AIDS vaccine trials - incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses 1994;10(Suppl 2):S201-5.
60. Wiebel WW, Jimenez A, Johnson W, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:282-9.
61. Longshore D, Anglin MD. Seroprevalence stable and seroconversions rare among injection drug users in Los Angeles. J Acquir Immune Defic Syndr Hum Retrovirol 1992;15:212-3.
62. Longshore D, Anglin MD. HIV prevalence and incidence among injection drug users in Los Angeles. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:738-9.
63. Kerndt PR, Weber M, Ford W, et al. HIV incidence among injection drug users enrolled in a Los Angeles methadone program. JAMA 1995;273:1831-2.
64. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-90. AIDS 1994;8:223-31.
65. Hahn JA, Vranizan KM, Moss AR. Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989-1990. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:157-64.
66. Lourie B, McFarland W, Kellogg TA, et al. Use of the sensitive/less sensitive EIA to monitor trends in HIV seroconversion among intravenous drug users at a drug treatment center in San Francisco, 1989-1998 [abstract ThOrC666]. In Program and abstracts of the XIII International Conference on AIDS, Durban, South Africa, July 2000.
67. Hagan H, McGough JP, Hansen GR, et al. Incidence of blood-borne viruses in a cohort of Seattle IDUS [abstract ThC222]. In Program and abstracts of the XI International Conference on AIDS, Vancouver, July 1996.
68. Thiede H, McGough JP, Hagan H, et al. Drug treatment and HIV risk reduction among injectors in Seattle, USA [abstract 23223]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
69. Edlin BR, Word CO, McCoy CB, et al. Differences in HIV epidemics among crack cocaine smokers in 3 cities [abstract I39]. In Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996.
70. Edlin BR, Irwin K, Faruque S, et al. Intersecting epidemics -crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994;331:1422-7.
71. Kassler W, Zenilman JM, Erickson B, et al. Seroconversion in patients attending sexually transmitted disease clinics. AIDS 1994,8:351-5.
72. Peterman TA, Zaidi AA, Wroten J. Decreasing prevalence hides a high HIV incidence: Miami. AIDS 1995;9:965-70.
73. Onorato IM, Klaskala W, Morgan WM, et al. Prevalence, incidence, and risks for HIV-1 infection in female sex workers in Miami, Florida. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:395-400.
74. Edlin BR, McCoy CB, Word CO, et al. High HIV incidence among young urban street-recruited crack cocaine smokers [abstract WeC226]. In Program and abstracts of the XI International Conference on AIDS, Vancouver, July 1996.
75. Klaskala W, Sosa C, Shor-Posner G, et al. High HIV seroconversion rate despite stable prevalence among sex partners of commercial sex workers in Miami, Florida, USA [abstract TuC2658]. In Program and abstracts of the XI International Conference on AIDS, Vancouver, July 1996.
76. Weedom J, Thomas P. HIV seroconversion among high-risk women in New York City. JAMA 1994;272:432-3.
77. Chirgwin KD, Feldman J, Dehovitz JA, et al. Incidence and risk factors for heterosexually acquired HIV in an inner-city cohort of women: temporal association with pregnancy. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:295-9.
78. Dominguez K, Ellerbrock TV, Harrington PE, et al. Risk factors for HIV seroconversion among young women in a rural community in the southeastern United States [abstract MoC222]. In Program and abstracts of the XI International Conference on AIDS, Vancouver, July 1996.
79. Marmor M, Morrow K, Smith C, et al. HIV risk behaviors among women who have sex with women (WSWs) enrolled in a high-risk US cohort [abstract 23500]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
80. Kelley PW, Redfield RR, Ward DL, et al. Prevalence and incidence of HTLV-III infection in a prison. JAMA 1986;256:2198-9.
81. Brewer TF, Vlahov D, Taylor E, et al. Transmission of HIV-1 within a statewide prison system. AIDS 1988;2:363-7.
82. Horsburgh CR, Jr, Jarvis JQ, McArther T, et al. Seroconversion to human immunodeficiency virus in prison inmates. Am J Public Health 1990;80:209-10.
83. Castro K, Shansky R, Scardino V, et al. HIV transmission in correctional facilities [abstract MC3067]. In Program and abstracts of the VII International Conference on AIDS, Florence, June 1991.
84. Rich JD, Dickinson BP, Macalino G, et al. Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. J Acquir Immune Defic Syndr 1999;22:161-6.
85. Kellogg T, McFarland W, Katz M. Use of HIV-antibody counseling and testing data to estimate time trends in HIV incidence in San Francisco [abstract 43482]. In Program and abstracts of the XII International Conference on AIDS, Geneva, June/July 1998.
86. Kellogg T, McFarland W, Katz M. Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco. AIDS 1999;13:2303.
87. Garland FC, Mayers DL, Hickey TM, et al. Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988. JAMA 1989;262:3161-5.
88. Warner RD, Mathis RE, Weston ME, et al. Estimates of human immunodeficiency virus (HIV) incidence and trends in the US Air Force. Vaccine 1993;11:534-7.
89. Cowan DN, Brundage JF, Pomerantz RS. The incidence of HIV infection among men in the United States Army Reserve components, 1985-1991. AIDS 1994;8:505-11.
90. Cowan DN, Brundage JF, Pomerantz RS. HIV infection among women in the Army Reserve components. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:171-6.
91. Renzullo PO, McNeil JG, Wann ZF, et al. Human immunodeficiency virus type-1 seroconversion trends among young adults serving in the United States Army 1985-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:177-85.
92. McNeil JG, Brundage JF, Wann ZF, et al. Direct measurement of human immunodeficiency virus seroconversions in a serially tested population of young adults in the United States Army, October 1985 to October 1987. N Engl J Med 1989;320:1581-5.
93. Glynn S, Kleinman S, Schreiber G, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. JAMA 2000;284:229-35.
94. Busch MP, Aberle-Grasse J, Rawal BD, et al. Demographic correlates of HIV incidence among US blood donors [abstract 272]. In Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January/February 1999.
95. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.